CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Curie Therapeutics
Curie Therapeutics

Curie Therapeutics

Curie Therapeutics, later Mariana Oncology, developed targeted radioligand cancer therapies, acquired by Novartis in 2024.

Boston, MA, US🇺🇸
Founded
2020
Overview
M & A
Compare
Fundraising
Employees
Library

Curie Therapeutics developed next-generation radiopharmaceuticals and peptide-targeted radioligand therapies for cancer treatment. Originally launched to pioneer rationally designed radionuclide conjugates, the biotechnology venture subsequently rebranded to Mariana Oncology to advance its lead clinical programs.

In May 2024, Novartis acquired Mariana Oncology for one billion dollars upfront to strengthen its radioligand pipeline and research infrastructure. The acquisition integrated Mariana's lead candidate MC-339 and therapeutic development platforms into Novartis oncology.

Curie Therapeutics - M & A Snapshot

Open M & A
  • Novartis

    Acquired Curie Therapeutics • Undisclosed • May 2, 2024

Curie Therapeutics - Quick Facts

Who are Curie Therapeutics' competitors?

Companies similar to Curie Therapeutics include Mariana Oncology, Radionetics Oncology, Ratio Therapeutics and Oncurie.

When was Curie Therapeutics founded?

Curie Therapeutics was founded in 2020.

Where is Curie Therapeutics' headquarters located?

Curie Therapeutics' headquarters is located in Boston, MA, US.

How much disclosed funding has Curie Therapeutics raised?

As of May 2, 2024, Curie Therapeutics has disclosed funding of $75M (USD). Undisclosed round amounts are excluded.

Curie Therapeutics - Classification

Ownership
  • Equity
  • Venture-backed
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Radiopharmaceuticals
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731

Curie Therapeutics - Similar Companies

Mariana Oncology logo

Mariana Oncology

Radionetics Oncology logo

Radionetics Oncology

radionetics.com

Ratio Therapeutics logo

Ratio Therapeutics

ratiotx.com

Oncurie logo

Oncurie

oncurie.com

Illumina Radiopharmaceuticals logo

Illumina Radiopharmaceuticals

Artbio logo

Artbio

artbio.com

Radiomedix logo

Radiomedix

radiomedix.com

Convergent Therapeutics logo

Convergent Therapeutics

convergentrx.com

Nucleus RadioPharma logo

Nucleus RadioPharma

nucleusrad.com

Radimmune Therapeutics logo

Radimmune Therapeutics

NuView Life Sciences logo

NuView Life Sciences

Aktis Oncology logo

Aktis Oncology

aktisoncology.com

Evergreen Theragnostics logo

Evergreen Theragnostics

evergreentgn.com

Trevarx Biomedical logo

Trevarx Biomedical

trevarx.com

Curis logo

Curis

curis.com

Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified